NeurOp Garners Additional Federal Funds
NeurOp Corporation, a preclinical stage pharmaceutical company focused on next generation drugs for CNS indications, announced today that it has received a Phase 1 SBIR award from the National Institute of Neurological Disorders and Stroke (NINDS). This grant is in addition to a $1.4MM SBIR Phase 2 award received by NeurOp from NINDS in September of 2006.

